Klamydiaarter Mycoplasmaarter Rickettsiaarter Legionellaarter * Aktivitet er tilfredsstillende påvist i kliniske undersøgelser. † Der er ikke påvist effekt af INVANZ i behandling af non- nosocomiel pneumoni grundet penicillin resistent Streptococcus pneumoniae. + frekvens for erhvervet resistens > 50% i nogle medlemslande # Methicillin- resistente stafylokokker (inklusiv MRSA) er altid resistente over for betalaktamer.
Chlamydia species Mycoplasma species Rickettsia species Legionella species * Activity has been satisfactorily demonstrated in clinical studies. † The efficacy of INVANZ in the treatment of community acquired pneumonia due to penicillin- resistant Streptococcus pneumoniae has not been established. + frequency of acquired resistance > 50% in some Member States # Methicillin-resistant staphylococci (including MRSA) are always resistant to betalactams.